THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) No, Sir.

(b) Does not arise.

(c) No amount has been recovered under Drug Prices Equalisation Account from 1st February, 1990 to 30th April, 1990.

Overcharging on Dexatopic Cream

310. SHRI MOHD. KHALEELUR RAHMAN:

SHRI RAJNI RANJAN SAHU:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) when his Ministry noticed about the overcharging on Dexatopic cream and when was the Company asked to furnish details;

(b) what steps have been taken to obtain the details;

(c) what are the reasons for not supplying the details asked for from the Company and what action has been taken against the company.

(d) what is the price of bulk drug taken in eight formulations in question;

(e) what are the names of price decontrolled medicines of the company where more than 100% MAPE is being enjoyed by the Company and what are the names of drugs involved in each case; and

(f) what are the names of bulk drugs being produced by the Company which are exempted from price control and what are the names of formulations being marketed based on each drug?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (c) In September, 1989 when it came to the notice of the Government that M/s. Infar are manufacturing and marketing Dexatopic Cream without price approval under the Drugs (Prices Control) Order, 1987, on 27.9.1989, the Company was asked to furnish certain details to the Government to enable it to calculate the amount over-charged by them on Dexatopic cream. Although the Company has submitted some information to the Government, the same is not sufficient to calculate the amount overcharged by them. As such the Company has been recently asked to furnish certain more details in the matter. The Director of Drug Control, West Bengal has also been requested to get the submission of the details by the Company expedited.

(d) Since the names of eight formulations have not been mentioned in the question, it is not possible to furnish the required information.

(e) and (f) The requisite information, to the extent available with the Government is given in the annexed statement.

Statement

	Name of the Formulation	Bulk drugs involved	
		Manufactured by the Company	Others
1	2	3	4
1.	*Deca Durabolin Inj. 10mg/ml	Nandrolone decanoate	
2.	*—do— 25mg/ml	—do—	
3.	*—do— 50mg/ml	—do—	

1	2	3	4
4.	–do– 100 mg/ml.	–do–	
5.	*Decabolin Injection	Nand. Ph. Propionate Desoxycorticosterone Ph.Propionate	
6.	*Durabolin Inj. 10mg/ml	Nand. Ph. Propionate	
7.	–do– 25mg/ml	–do–	
8.	Gestanin tabs.	Allylestrenol	
9.	*Lynoral tabs. 0.01mg.	Ethinylestradiol	
10.	*–do– 0.05mg	–do–	
11.	–do– 1mg.	–do–	
12.	Menstrogen tab. 0.02mg	Ethinylestradiol Progesterone	
13.	Menstrogen tab. 0.01mg	Ethinylestradiol Ethisterone	
14.	Menstrogen Forte 50mg/ml	Progesterone Oestradiol Benzoaet	
15.	*Mixogen tab, 0.004mg	Ethinylestradiol Methyl Testosterone	
16.	*Mixogen Amp.	Oestradiol Benzoate Oestradiol Ph. Propionate Testosterone Propionate Testosterone Ph. Propionate Testosterone Isocaproate	
17.	Orabolin tab. 2mg.	Ethylestrenol	
18.	–do– Inj. 5ml.	Ethylestrenol	
19.	*Sustanon '100' Inj.	Testosterone Propionate Testosteroae Ph. Prop. Testosterone Isocaproate	
20.	Sustnon '250' Inj.	Testosterone Propionate Testosterone Ph. Pro . Tesstosterone Isocatoate Testosterone Decanoate	
21.	Testanon '25' Inj.	Testosterone Propionate	
22.	*Testanon '50' Inj.	Testosterone Ph. Prop.	
23.	Pavulon Inj. 2ml		Pancuronium Bromite
24.	Lyndiol Tab. 1mg.		Lynestrenol Ethinylestradiol
25.	Orgalutin tab.		Lynestrenol Ethinylestradiol
26.	Orgametril tab.		Lynestrenol

*Formulations where the company is enjoying MAPE of more than 100%.